Corporate Transactions

How We Are Different

Seasoned M&A Experts
We think like investors, provide transaction leadership with world-class consultants, and maximize value with real-world operators.

Relentless Focus on Value Creation
We are willing to place fees at risk as part of our relentless commitment to meeting and exceeding your value creation objectives.

Free From Audit Conflict
We provide services across the deal lifecycle without conflicts, ensuring auditors can stay focused on their responsibilities.

Interim Leadership
We provide interim executive leadership, providing the time and flexibility you may need to bring in the right long-term leadership roles.

Specialized Industry Expertise
We access and leverage a global network of industry experts to provide tailored insights and solutions.

Proven Track Report
We have a track record of delivering successful outcomes in high-stakes, cross-border transactions.

Discover our A&M CTG Insights

The Inflation Reduction Act: Is It Good or Bad for Drug Innovation?

In August 2022, the United States took a significant legislative step with the passage of the Inflation Reduction Act (IRA). Among the various sectors impacted, the pharmaceutical industry is poised to be particularly affected as it stands at a critical juncture, especially concerning prescription drug pricing reform. This legislation brings to the fore a vital question: What impact will the IRA have on drug innovation?

M&A After the FTC’s Non-compete Ban: Can Garden Leave Structures Fill the Gap?

In a move that's set to reshape the landscape of mergers and acquisitions (M&A), the Federal Trade Commission (FTC) recently decided to ban noncompete agreements, an act that has sent ripples through the corporate world. Traditionally, noncompete clauses had been a staple in mitigating risks associated with M&A activities, especially concerning the retention of key personnel and preventing them from becoming direct competitors shortly after transactions. However, this regulatory shift will necessitate a reevaluation of risk management strategies and garden leave structures — which may require employees to stay away from the workplace after termination while being compensated — are emerging as a viable alternative to safeguard business interests during critical transition periods.

Welcome to the Future: CTG M&A Thought Leadership Series

In the world of M&A, staying ahead of the competition is more than just an advantage- it’s a necessity. Introducing "Welcome to the Future," a multi-media thought leadership series brought to you by A&Ms Corporate Transactions Group (CTG).

A&M CTG’s Insight-Oriented Approach Will Disrupt M&A Industry Norms

A&M CTG’s pioneering approach is more than just a novel strategy; it's a harbinger of the industry's evolution. By challenging conventional wisdom and daring to imagine a different way of doing business, A&M is not just reshaping the landscape of corporate transactions and consulting, it's setting the stage for a revolution that promises to sweep the professional industry by storm.

Unlock Insights with The Latest Automotive M&A Trends Report

We are thrilled to announce the release of our new automotive M&A report- utilizing the most current data and reporting from year-end 2023.

Corporate Transactions

Alvarez & Marsal’s Corporate Transactions Group (CTG) provides an end-to-end M&A solution that offers rapid insights and optimizes value. Our functional, operational, and industry experts achieve differentiated outcomes across all phases of a transaction.